Lorazepam is a benzodiazepine medication commonly used as the sedative and anxiolytic of choice in the inpatient setting owing to its fast (1 to 3 minute) onset of action when administered intravenously. Lorazepam is also one of the few sedative-hypnotics with a relatively clean side effect profile. This activity covers lorazepam, including mechanism of action, pharmacology, adverse event profiles, eligible patient populations, monitoring, and highlights the interprofessional team's role in managing lorazepam therapy.
Identify the mechanism of action of lorazepam.
Summarize the various indications for initiating therapy with lorazepam.
Describe the adverse events of lorazepam.
Review interprofessional team strategies for improving care coordination and communication to properly use lorazepam to improve patient outcomes in the varied scenarios where lorazepam is effective.
Lorazepam is a benzodiazepine medication developed by DJ Richards. It went on the market in the United States in 1977. Lorazepam has common use as the sedative and anxiolytic of choice in the inpatient setting owing to its fast (1 to 3 minute) onset of action when administered intravenously. Lorazepam is also one of the few sedative-hypnotics with a relatively clean side effect profile.
Chemotherapy-associated anticipatory nausea and vomiting (adjunct or breakthrough)
Mechanism of Action
Lorazepam binds to benzodiazepine receptors on the postsynaptic GABA-A ligand-gated chloride channel neuron at several sites within the central nervous system (CNS). It enhances the inhibitory effects of GABA, which increases the conductance of chloride ions into the cell. This shift in chloride ions results in hyperpolarization and stabilization of the cellular plasma membrane. Its inhibitory action in the amygdala is beneficial in anxiety disorders, while its inhibitory activity in the cerebral cortex is beneficial in seizure disorders.
Lorazepam can be administered orally (0.5 mg tablet, 1 mg tablet, 2 mg tablet, oral concentrate solution 2 mg/mL, 1 mg extended-release capsule, 2 mg extended-release capsule, and 3 mg extended-release capsule). It can be administered via intravenous(IV) or intramuscular(IM) injection (2 mg/mL solution, and 4 mg/mL solution). The onset of its action is 1 to 3 minutes if administered IV and 15 to 30 minutes if administered IM. Lorazepam immediate-release tablet reaches its peak plasma time in 2 hours if administered orally. Lorazepam has an 85% bioavailability when taken by mouth and is metabolized in the liver by glucuronidation using the CYP450 enzymes, and has a half-life of 14 hours.
The initial starting dose is 2 mg to 3 mg orally, can repeat dose 2 to 3 times per day; the maximum dosage is 10 mg per day.
Insomnia due to Anxiety or Stress
In patients less than 65 years of age, the dose is 0.5 to 2 mg orally at bedtime, and in patients over 65 years of age, the dose is reduced to 0.5 to 1 mg at bedtime.
Premedication for Anesthesia
If given IM, the dose is 0.05 mg/kg administered 2 hours before surgery (maximum dose 4 mg). If administered IV, the dose is 0.044 mg/kg administered 15 to 20 minutes before surgery (maximum dose 4 mg). In patients older than 50 years of age, the maximum dosage is 2 mg.
Administered IV, the dose is 0.1 mg/kg (maximum dose 4 mg), at a maximum rate of 2 mg per minute; may repeat in 5 to 10 minutes Note: Must dilute dose with 1:1 saline.
Agitation in the Intensive Care Unit (ICU) Patient (off-label use)
IV Loading dose is 0.02 to 0.04 mg/kg (maximum single dose 2 mg); Maintenance dose is 0.02 to 0.06 mg/kg every 2 to 6 hours as needed or 0.01 to 0.1 mg/kg per hour with a maximum dosing of less than 10 mg per hour.
Alcohol Withdrawal Delirium (off-label use)
IV dose is 1 to 4 mg every 5 to 15 minutes until the patient is calm; can repeat every hour as needed. IM dose is 1 to 4 mg every 30 to 60 minutes until the patient is calm; can repeat every hour as needed.
Alcohol Withdrawal Syndrome (off-label use)
The symptom-triggered regimen can be administered orally, intramuscularly, or intravenously at 2 mg to 4 mg per hour as needed; the severity assessment scale must determine the dose. The fixed-dose regimen can be administered orally, intramuscularly, or intravenously at 2 mg every 6 hours for four doses, followed by 1 mg every 6 hours for eight additional doses. Note: Symptom-triggered regimen is preferable to the fixed-dose regimens; lower doses and shorter treatment duration are in order.
Chemotherapy-associated Nausea and Vomiting (off-label use)
Lorazepam is used for breakthrough nausea/vomiting or adjunct to standard antiemetics. It can be given orally, intravenously, or sublingually at 0.5 to 2 mg every 6 hours as needed.
Psychogenic Catatonia (off-label use)
IM dose is 1 mg to 2 mg; can repeat the dose in 3 hours then again in another 3 hours if the initial and subsequent doses are ineffective. It can be administered orally, intramuscularly, or intravenously; initially, 1 mg and may repeat in 5 minutes if necessary. If the initial challenge is unsuccessful, one may increase the dose up to 4 to 8 mg per day and may continue treatment for up to 5 days.
Pregnant Women: It is pregnancy category D medicine. There are documented case reports and case-control studies showing an increased risk for cleft palate and cleft lip using lorazepam and other benzodiazepines in the first trimester. Third-trimester use of lorazepam and benzodiazepine is associated with an increased risk of causing neonatal withdrawal symptoms. If lorazepam needs to be used in pregnancy, it should be used with extreme caution, and the benefit has to outweigh the risk.
Breastfeeding Women: Lorazepam is found in low levels in breastmilk. Studies report that it does not cause adverse reactions in breastfed babies with standard maternal dosages. A safety scoring system of psychotropic drugs used in lactating women found lorazepam safer than other benzodiazepines during breastfeeding.
Hepatic Impairment: Product labeling does not have information on using lorazepam in patients with hepatic impairment.
Renal Impairment: Manufactures recommend precautions in case of using frequent doses of lorazepam over relatively short periods in patients with renal disease.
Like most benzodiazepines, adverse reactions to lorazepam include CNS and respiratory depression, which are dose-dependent. More severe effects occur with high doses.
Paradoxical reaction; hyperactive and aggressive behavior
Withdrawal symptoms if abruptly discontinued after long-term use.
Propylene glycol toxicity when using the parenteral formulation
Common adverse effects of lorazepam include:
Local injection site reaction
Hypoventilation with IV use
AST and ALT elevation
Lorazepam has drug interaction with other drugs, which cause CNS depression. Concomitant use of sedatives, hypnotics, opioids, cough and cold medicines, antiepileptics, muscle relaxers, and alcohol can worsen adverse reactions caused by lorazepam. If a patient starts treatment with UDP-glucuronosyltransferase (UGT) inhibitors, then taper off lorazepam to discontinue.
Lorazepam is contraindicated in patients with an anaphylactic reaction to lorazepam, any component of the formulation, other benzodiazepines (cross-sensitivity with other benzodiazepines may exist).
It is contraindicated to use in neonates or premature infants, in patients with severe respiratory impairment (except during mechanical ventilation), acute narrow-angle glaucoma, sleep apnea, severe respiratory insufficiency, and intra-arterial administration route.
Lorazepam and other benzodiazepines should not be first-line agents for anxiety and other psychiatric disorder symptoms in the first and third trimester of pregnancy.
Lorazepam and other benzodiazepines have an increased risk of abuse, misuse, and dependence; these medications are contraindicated in the patient who is actively using illicit substances and drugs. Except for use in Alcohol withdrawal disorder symptoms and detoxification, lorazepam and other benzodiazepine are contraindicated in patients with a history of alcohol dependence and abuse and not in remission. Increased risk of fatality with the combined use of alcohol and lorazepam in overdose, including death.
Injection formulation contains polyethylene glycol, propylene glycol, or benzyl alcohol, so contraindications include hypersensitivity to these excipients. Extended-release capsules contain tartrazine, and hence patients who history of an allergic reaction should avoid capsules.
Monitor respiratory and cardiovascular status, blood pressure, heart rate, and symptoms of anxiety.
With Long-term therapy, monitor CBC, liver function tests, and LDH. With high-dose or continuous IV use or IV use in patients with renal impairment, monitor clinical signs of propylene glycol toxicity, serum creatinine, BUN, serum lactate, and osmolality gap. With critically ill patients, monitor the depth of sedation.
Lorazepam is a Schedule IV drug, and patients may develop dependence and tolerance with long-term use. The recommendation is to use the lowest possible effective dose for the shortest period. When stopping lorazepam, it should be tapered by 0.5 mg every three days to avoid withdrawal symptoms.
Lorazepam can cause CNS and respiratory depression in overdose. It can lead to hypotension, ataxia, confusion, coma, extreme drowsiness, muscle weakness, and death. Concurrent use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Concomitant prescribing of benzodiazepines and opioids must be reserved for patients for whom alternative treatment options are inadequate. Dosage and duration of lorazepam must be limited to the minimum required. Patients require surveillance for signs and symptoms of respiratory depression. Lorazepam, as with other benzodiazepines, is rarely associated with elevations in serum ALT, and clinically apparent liver injury from lorazepam is extremely rare.
The clinical pattern of acute liver injury from benzodiazepines is typically cholestatic. Flumazenil is an antidote for benzodiazepine toxicity. Flumazenil competes with benzodiazepines for binding at the GABA/benzodiazepine receptor complex. Abrupt awakening can cause dysphoria, agitation, and increased adverse effects. If administered to patients on chronic benzodiazepine therapy, the sudden interruption of benzodiazepine antagonism by flumazenil can induce benzodiazepine withdrawal, including seizures. Flumazenil has minimal effects on benzodiazepine-induced respiratory depression, and suitable ventilatory support should be available in treating acute benzodiazepine overdose.
Enhancing Healthcare Team Outcomes
Lorazepam, like other benzodiazepine medications, can be a highly addictive medication. As a result, an interprofessional team approach to prescribing and managing these medications is necessary. This team includes the prescribers (MDs, DOs, NPs, PAs), psychiatrists, nursing staff, and pharmacists, each of whom must be vigilant for signs of misuse or adverse effects. This approach will prevent misuse, unintended adverse events and optimize therapy. [Level 5]
Great care is necessary when prescribing lorazepam at high doses or prolonged durations, particularly in patients with a history of substance use disorder or concurrent opioid prescriptions. Managing such patients requires an interprofessional team of healthcare professionals, including nurses, pharmacists, and several specialist physicians, to monitor for signs of abuse, diversion, or concomitant use with other prescription or non-prescription sedative medications. Prescribers and pharmacists must monitor treatment, provide patient education, be vigilant in prescribing benzodiazepines such as lorazepam. The healthcare team should use state and federal controlled substance monitoring and diversion databases to identify high-risk patients with multiple and frequent prescriptions for benzodiazepines, opioids, muscle relaxants, and other sedative-hypnotics. Safe prescribing is only achievable with interprofessional treatment monitored by both the clinician and pharmacist. [Level 5]
(Click Image to Enlarge)
Lorazepam chemical structure
Contributed from the Public Domain
Hui D, Benzodiazepines for agitation in patients with delirium: selecting the right patient, right time, and right indication. Current opinion in supportive and palliative care. 2018 Sep 19 [PubMed PMID: 30239384]
Yeary J,Garavaglia J,McKnight R,Smith M, Change in Management of Status Epilepticus With the Addition of Neurointensivist-Led Neurocritical Care Team at a Rural Academic Medical Center. Hospital pharmacy. 2018 Oct [PubMed PMID: 30210147]
Maurice-Szamburski A,Auquier P,Viarre-Oreal V,Cuvillon P,Carles M,Ripart J,Honore S,Triglia T,Loundou A,Leone M,Bruder N, Effect of sedative premedication on patient experience after general anesthesia: a randomized clinical trial. JAMA. 2015 Mar 3 [PubMed PMID: 25734733]
Heavner JJ,Akgün KM,Heavner MS,Eng CC,Drew M,Jackson P,Pritchard D IX,Honiden S, Implementation of an ICU-Specific Alcohol Withdrawal Syndrome Management Protocol Reduces the Need for Mechanical Ventilation. Pharmacotherapy. 2018 May 25 [PubMed PMID: 29800507]
Cevher Binici N,Topal Z,Demir Samurcu N,Cansız MA,Savcı U,Öztürk Y,Özyurt G,Tufan AE, Response of Catatonia to Amisulpride and Lorazepam in an Adolescent with Schizophenia. Journal of child and adolescent psychopharmacology. 2018 Mar [PubMed PMID: 29406775]
Naso AR, Optimizing patient safety by preventing combined use of intramuscular olanzapine and parenteral benzodiazepines. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2008 Jun 15 [PubMed PMID: 18541690]
Wilson KC,Reardon C,Theodore AC,Farber HW, Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. Chest. 2005 Sep; [PubMed PMID: 16162774]
Barnes BJ,Gerst C,Smith JR,Terrell AR,Mullins ME, Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. Pharmacotherapy. 2006 Jan; [PubMed PMID: 16422667]
Petrides AK,Melanson SEF,Kantartjis M,Le RD,Demetriou CA,Flood JG, Monitoring opioid and benzodiazepine use and abuse: Is oral fluid or urine the preferred specimen type? Clinica chimica acta; international journal of clinical chemistry. 2018 Jun [PubMed PMID: 29499200]
Rubio González V,Redondo Martín S,Ruíz López Del Prado G,Muñoz Moreno MF,Velázquez Miranda A, [Hospital Emergencies Associated with the Consumption of Hypnotics and Sedatives, 2009-2013,Castilla y León, Spain]. Revista espanola de salud publica. 2016 Oct 24 [PubMed PMID: 27775683]
Use the mouse wheel to zoom in and out, click and drag to pan the image